BioLineRx Ltd.

Regulatory Filings • Nov 5, 2014

_________ false

C003������� �� ��� ��"�2PublicBIOLINE RX LTD8688Corporation no: 513398750Stock Exchange/Market: NASDAQ-SC2271381����� 19 , ������� 91450 , ,Tel: 02-5489100 , 02-5489116 Fax: 02-5489101E.mail address: info@BioLineRx.comReported via MAGNA: 05/11/2014              Time of broadcast: 13:47 13:45:19

Reference: 2014-02-188526

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on	BioLineRx Announces Successful Final Results of Phase 1/2 Study for Novel Celiac Treatment

6-K_BL7010_051114_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity:
Date of revision of form structure: 03/09/2014
- - -
Name of the Signatory: : Serlin Philip Adam , Position of Signatory in the reporting corporation: Chief Financial Officer , Name of Employer Company: .
Hartum Telephone: 02-5489100 , Facsimile: 02-5489101 , E-mail: phils@biolinerx.com 1